Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine

Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–36.

Article  Google Scholar 

Ahmed F, Gaul C, Garcia-Monco JC, Sommer K, Martelletti P, Investigators RP. An open-label prospective study of the real-life use of OnabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. J Headache Pain. 2019;20(1):26.

Article  Google Scholar 

Stark C, Stark R, Limberg N, Rodrigues J, Cordato D, Schwartz R, et al. Real-world effectiveness of OnabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study. J Headache Pain. 2019;20(1):81.

Article  Google Scholar 

Khalil M, Zafar HW, Quarshie V, Ahmed F. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK. J Headache Pain. 2014;15:54.

Article  Google Scholar 

Escher CM, Paracka L, Dressler D, Kollewe K. Botulinum toxin in the management of chronic migraine: clinical evidence and experience. Ther Adv Neurol Disord. 2017;10(2):127–35.

Article  CAS  Google Scholar 

Ornello R, Ahmed F, Negro A, Miscio AM, Santoro A, Alpuente A, et al. Early management of OnabotulinumtoxinA treatment in chronic migraine: insights from a Real-Life European Multicenter Study. Pain Ther. 2021;10(1):637–50.

Article  Google Scholar 

Lanteri-Minet M, Ducros A, Francois C, Olewinska E, Nikodem M, Dupont-Benjamin L. Effectiveness of OnabotulinumtoxinA (BOTOX(R)) for the preventive treatment of chronic migraine: a meta-analysis on 10 years of real-world data. Cephalalgia. 2022;42(14):1543–64.

Article  Google Scholar 

Bendtsen L, Sacco S, Ashina M, Mitsikostas D, Ahmed F, Pozo-Rosich P, et al. Guideline on the use of OnabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain. 2018;19(1):91.

Article  Google Scholar 

Guidelines NICE. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. 2021.

Sacco S, Russo A, Geppetti P, Grazzi L, Negro A, Tassorelli C, et al. What is changing in chronic migraine treatment? An algorithm for OnabotulinumtoxinA treatment by the Italian chronic migraine group. Expert Rev Neurother. 2020;20(12):1275–86.

Article  CAS  Google Scholar 

Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention—2022 update. J Headache Pain. 2022;23(1):67.

Article  Google Scholar 

Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F. Long-term effectiveness of three anti-CGRP monoclonal antibodies in resistant chronic migraine patients based on the MIDAS score. CNS Drugs. 2022;36(2):191–202.

Article  CAS  Google Scholar 

Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6.

Article  Google Scholar 

Cernuda-Morollon E, Martinez-Camblor P, Ramon C, Larrosa D, Serrano-Pertierra E, Pascual J. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine. Headache. 2014;54(6):987–95.

Article  Google Scholar 

Armanious M, Khalil N, Lu Y, Jimenez-Sanders R. Erenumab and OnabotulinumtoxinA combination therapy for the prevention of intractable chronic migraine without aura: a retrospective analysis. J Pain Palliat Care Pharmacother. 2021;35(1):1–6.

Article  CAS  Google Scholar 

Mechtler L, Saikali N, McVige J, Hughes O, Traut A, Adams AM. Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to OnabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine. Front Neurol. 2021;12: 788159.

Article  Google Scholar 

Silvestro M, Tessitore A, Scotto di Clemente F, Battista G, Tedeschi G, Russo A. Additive interaction between Onabotulinumtoxin-A and erenumab in patients with refractory migraine. Front Neurol. 2021;12:656294.

Article  Google Scholar 

Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L, et al. Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to OnabotulinumtoxinA: a retrospective chart review. Pain Ther. 2021;10(2):809–26.

Article  Google Scholar 

Cohen F, Armand C, Lipton RB, Vollbracht S. Efficacy and tolerability of calcitonin gene-related peptide-targeted monoclonal antibody medications as add-on therapy to OnabotulinumtoxinA in patients with chronic migraine. Pain Med. 2021;22(8):1857–63.

Article  Google Scholar 

Ailani J, Pearlman E, Zhang Q, Nagy AJ, Schuh K, Aurora SK. Positive response to galcanezumab following treatment failure to OnabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies. Eur J Neurol. 2020;27(3):542–9.

Article  CAS  Google Scholar 

Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D, et al. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2018;38(10):1611–21.

Article  Google Scholar 

Ferrari MD, Zuurbier KWM, Barash S, Ning X, Cohen JM. Fremanezumab in individuals with chronic migraine who had inadequate response to OnabotulinumtoxinA and topiramate or valproic acid. Headache. 2022;62(4):530–3.

Article  Google Scholar 

Lambru G, Hill B, Murphy M, Tylova I, Andreou AP. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 2020;21(1):61.

Article  CAS  Google Scholar 

Pensato U, Baraldi C, Favoni V, Cainazzo MM, Torelli P, Querzani P, et al. Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. Neurol Sci. 2022;43(2):1273–80.

Article  Google Scholar 

Raffaelli B, Kalantzis R, Mecklenburg J, Overeem LH, Neeb L, Gendolla A, et al. Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and OnabotulinumtoxinA: a dual-center retrospective observational study. Front Neurol. 2020;11:417.

Article  Google Scholar 

The Lancet N. Complicated decisions on new migraine-prevention therapies. Lancet Neurol. 2019;18(3).

Overeem LH, Peikert A, Hofacker MD, Kamm K, Ruscheweyh R, Gendolla A, et al. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalagia. 2021;13:291–301.

Google Scholar 

Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.

Frampton JE. OnabotulinumtoxinA in chronic migraine: a profile of its use. CNS Drugs. 2020;34(12):1287–98.

Article  CAS  Google Scholar 

Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F. Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. Eur J Neurol. 2022.

Charles A. A new opportunity after migraine treatment failure? Lancet. 2018;392(10161):2241–2.

Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358–73.

Article  Google Scholar 

Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack AA. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13.

Article  Google Scholar 

Guerzoni S, Baraldi C, Pani L. The association between OnabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraine. Neurol Sci. 2022.

Ornello R, Ahmed F, Negro A, Miscio AM, Santoro A, Alpuente A, et al. Is there a gender difference in the response to OnabotulinumtoxinA in chronic migraine? Insights from a Real-Life European Multicenter Study on 2879 patients. Pain Ther. 2021;10(2):1605–18.

Article  Google Scholar 

Altamura C, Cevoli S, Brunelli N, Aurilia C, Fofi L, Egeo G, et al. When should we consider chronic patients as non-responders to monoclonal antibodies targeting the CGRP pathway? J Neurol. 2022;269(2):1032–4.

Article  CAS  Google Scholar 

Stovner LJ, Hagen K, Tronvik E, Bruvik Gravdahl G, Burstein R, Dodick DW. FollowTheSutures: piloting a new way to administer OnabotulinumtoxinA for chronic migraine. Cephalalgia. 2022;15:3331024211067775.

Google Scholar 

留言 (0)

沒有登入
gif